4-Hydroxyandrostenedione treatment for postmenopausal patients with advanced breast cancer.
We have treated 128 postmenopausal women with advanced breast cancer with 4-hydroxyandrostenedione. Of these, 118 were assessable for toxicity and 100 for response to treatment. Response to therapy was seen in 34% of patients and stabilization of disease in 12 patients. Three dose regimens were used (500 mg intramuscularly weekly; 250 mg intramuscularly every 2 weeks; and 500 mg orally daily). There was no difference in response in these three groups. Side effects were minimal and local reaction to injected drug was seen in 13% of patients. The sole severe side effect observed was neutropenia which was transient and reversible on discontinuing therapy. 4-Hydroxyandrostenedione is an effective nontoxic agent in the treatment of breast cancer.
D000284:Administration, Oral; D000735:Androstenedione / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000503:physiopathology; D005260:Female; D006801:Humans; D007273:Injections, Intramuscular; D008593:Menopause / Q000187:drug effects*; D009376:Neoplasms, Hormone-Dependent / Q000188:drug therapy / Q000503:physiopathology; D011960:Receptors, Estrogen / Q000032:analysis / Q000187:drug effects
D011960:Receptors, Estrogen; D000735:Androstenedione; C014594:formestane